CytoCore's InPath System Upgrades Pap Test with FDA Approved e2 Collector; New Drug Delivery System Offers Treatment Options for Cervical Lesions.

CHICAGO -- CytoCore, Inc. (OTCBB: MCDG), with its recent product licenses, has assembled in four product components called the InPath System NG, a unique and complete system to address the various aspects of the traditional Pap test : the e2 Collector, the CVX/GCI Assay, the AIPS automated microscopy platform, and a new Drug Delivery System. Each product is an enhancement or upgrade to the current methods being used with the Pap test today.

The e2 Collector which is FDA approved and will be available for sale late summer this year, starts the Pap test with a proven more accurate cell collection than the current spatula and brush method. The results of the FDA trial demonstrated that for women with an abnormal Pap test, the e2 Collector because of its patented design and functionality is able to collect a better sampling of cells from the opening and into the cervical canal. In the FDA trial, the Collector produced zero false positives and half the false negatives of the spatula and brush. The company believes that this product will be of special interest to women who have recently tested positive for the newly introduced HPV test. Patients with this virus would more likely have the abnormal PAP tests. The e2 Collector will provide the best collection of cells available making sure the patient's test is the most accurate possible.

The Pap test slide will be analyzed with the new CVX/GCI Assay which uses a unique patent pending combination of bio-markers to accurately identify cells that are turning cancerous or about to turn cancerous. Using a technology called proteomics, the Assay turns these target cells a fluorescent color so they can be identified more accurately and easily. Initial lab tests indicate this Assay has accuracy rates from 87% to 100% accurate. These numbers compare very favorably with current Pap test rates which range from 50-70% accurate. And, the bio-marker Assay will deliver these results 7/24 without fatigue or a drop off in performance. Patient trials will commence later this year.

The next component, the Automated Image Proteomic System (AIPS), an automated image guided microscopy screening system, automatically scans the slide(s) for the presence of fluorescence and marked cells, and defines their location in the software database. Then later, it will guide the operator to the marked cell's location, allowing the trained Cytologist to spend their time examining these marked cells for the presence of cancer, not spending their time looking through hundreds of thousands of cells for those few that might be dangerous. CytoCore believes the combination of the CVX/GCI Assay and the AIPS platform will bring a new unmatched level of accuracy to the Pap test. The product combination of the Assay and AIPS system has been designed so that it can produce an accurate cervical cancer screening test anywhere in the world. This combination should be especially helpful to those women and their countries that do not now have access to Pap tests because of a lack of available cytologists and laboratories. The AIPS system will be available for manufacturing and testing this summer.

The last component of the InPath System is the new patent pending Drug Delivery System, providing for the first time a therapeutic treatment option for early stage cervical lesions. This system is based on a modification of the e2 Collector combined with existing FDA approved Patch technology. The Patch technology will provide the ability to deliver drug compounds in a controlled release manner, directly, specifically, and safely to the cervical surface. With partners, the Company expects to develop several compounds for the Patch: a mild to moderate chemo compound, an anti-viral compound for treating the HPV virus, and an immune-enhancement compound. These various Patch compounds should give to the physician for the first time real choices in how to address moderate to high grade cervical lesions. The Company expects to commence patient trials later this year.

CytoCore's CEO, Dr. David Weissberg stated: "With the recent announcements of the two new products we've licensed from University Hospital's of Cleveland in association with Dr. George Gorodeski, CytoCore now has a complete System to address the issues and requirements of Cervical Cancer screening and treatment. Each of the four components of the InPath System will deliver a significant improvement to the current methods now used with the Pap test to collect and analyze cells. The e2 Collector improves the cell collection and therefore the accuracy of the Pap test; the CVX/CGI Assay should significantly increase the accuracy of identifying potentially dangerous cells; the AIPS platform will scan and locate the marked cells for cytologist thereby improving the screening accuracy; and then the Drug Delivery System will give the physician a for the first time a choice on how to respond to the abnormal Pap test. While each of these products can be used separately, there is nothing even remotely like this product combination on the market today. We expect the InPath System to become a significant force in reducing the risk of cervical cancer among women world wide."

Dr George Gorodeski, head of CytoCore's Medical Advisory Board and its director of basic research stated, "With these products, CytoCore has assembled a fully integrated System that uses state of the art technology to significantly upgrade each aspect of the Pap test offering a very large increase in its capability, accuracy and reliability. In my opinion as a life long Gynecological Physician and Researcher, the InPath System is truly unique, and it will make a major impact with the Pap test and the whole area of Cervical Cancer detection and treatment, thereby saving many lives both here and around the world."

About CytoCore Inc.

CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with a highly accurate, low-cost, cervical cancer screening and treatment system that can be integrated into existing medical models or at the point-of-care. More information is available at: www.Molecular-Dx.com

Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2004 and its Quarterly Reports on Form 10-QSB for the quarters ended June 30, 2005 and September 30, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.